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Abstract The Menkes (MNK) protein is a vital component of
copper homeostasis in mammalian cells. In this paper we provide
the first biochemical evidence that the MNK protein functions as
a copper-translocating P-type ATPase in mammalian cells. The
enzyme activity in membrane vesicles prepared from Chinese
hamster ovary cells overexpressing MNK was ATP-dependent,
correlated with the amount of MNK and followed Michaelis-
Menten kinetics with respect to copper. The copper transport
was observed only under reducing conditions suggesting MNK
transports Cu(I). This study opens the way to detailed structure-
function studies and assessment of functional MNK derived from
patients with Menkes disease.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Copper is an essential trace element which is required for
the activity of a number of essential enzymes, e.g. Cu-Zn
superoxide dismutase, lysyl amine oxidase, cytochrome c ox-
idase and dopamine L-hydroxylase [1]. Nevertheless high con-
centrations of copper can pose a danger, because intracellular
redox potential, controlled primarily by thiols and anti-oxi-
dant enzymes, can cause the reduction of Cu(II) to Cu(I) with
reactive oxygen species being formed as side-products [2]. It is
probable that all cells have an e⁄cient system for regulating
copper homeostasis, which involves uptake, delivery to appro-
priate cell compartments and enzymes and, ¢nally, e¥ux from
the cell.
Menkes disease is an X-linked genetic disorder of copper
transport in humans caused by mutations in the Menkes gene
(ATP7A), which encodes the Menkes protein, hMNK. The
disease is caused by gross systemic Cu de¢ciency, mainly
due to defective intestinal absorption of Cu associated with
accumulation of copper in gut mucosa [3^5]. Neurological
symptoms observed in Menkes patients are believed to be
due to de¢ciencies in the activity of copper-dependent cyto-
chrome c oxidase, Cu-Zn superoxide dismutase and dopamine
L-hydroxylase [3,4], while lysyl oxidase de¢ciency is responsi-
ble for the abnormalities of connective tissue [3,4,6]. The ac-
cumulation of copper in cell lines derived from Menkes pa-
tients compared to normal cells [7^11] concomitant with
decreased activity of copper-containing lysyl oxidase
[6,12,13] suggests that the delivery of copper to various cellu-
lar compartments is a signi¢cant aspect of Menkes disease.
Taken together, all these ¢ndings support the concept that
the primary cause of Menkes disease is impaired copper ho-
meostasis.
Consistent with the above ¢ndings, a candidate gene for the
hMNK protein has been cloned [14^16], and the deduced
amino acid sequence suggested the protein contains several
regions which are highly conserved among all P-type ATPases
[17]. These enzymes are commonly involved in the transport
of various cations (e.g. Ca, Cd and Hg) across biological
membranes [18,19]. Moreover, structural hMNK homologues,
which have been characterised in yeasts, CCC2 [20], and pro-
karyotes, CopB [21] are involved in Cu transport. MNK
mRNA has been found in most tissues, except the liver, in
mammals, including humans. Previous studies from our labo-
ratory provided clear evidence of the ability of copper-resist-
ant chinese hamster ovary (CHO) cell lines, CUR2 and
CUR3, derived from the parental strain, CHO-K1, to with-
stand high concentrations of extracellular copper due to en-
hanced copper e¥ux. This correlated well with overexpression
of chMNK in these cells resulting from gene ampli¢cation
[22]. The chMNK protein has more than 90% homology to
hMNK [22], so it is assumed that these proteins will have
similar Cu-transporting activities.
In the present study, an in vitro vesicle assay was used to
provide the ¢rst direct biochemical evidence that the mamma-
lian MNK homologue is a copper-transporting P-type AT-
Pase. To establish unequivocally that the ATP-dependent
translocation of copper was due to the chMNK protein, use
was made of parental CHO-K1 cells and their copper-resistant
variants, which overexpress the MNK protein by up to 70-
fold [22].
2. Materials and methods
2.1. Plasma membrane enriched vesicle preparation
CHO-K1, CUR2 and CUR3 (copper-resistant cells which overex-
press chMNK [22]) were cultured in basal Eagle’s medium with
Earle’s salts supplemented with 10% foetal bovine serum, 2 mM L-
glutamine, 0.2 mM proline, 1.2 mM NaHCO3 and 20 mM HEPES
[22]. The cells were grown as a monolayer on 900 cm2 roller bottles
until con£uent (approximately 107 cells). The cells were incubated in
growth medium supplemented with 189 WM CuCl2 for 2 h prior to
being harvested by scraping into cold phosphate bu¡ered saline, and
pelleted at 1000Ug for 10 min. The resulting pellet was snap frozen
and stored at 370‡C until further use.
Vesicles used in this experiment were prepared according to the
procedure for preparing plasma membrane enriched vesicles described
by Schlemmer and Sirotnak [23] except that the 9800Ug centrifuga-
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tion and dialysis steps were omitted. All bu¡ers contained antipro-
teases: phenylmethylsulphonyl £uoride (100 Wg/ml), leupeptin (0.5 Wg/
ml), pepstatin (1 Wg/ml) and aprotinin (1 Wg/ml). Protein concentra-
tion of the vesicle preparation was determined using Bio-Rad protein
reagent (Bio-Rad Laboratories) [24]. Vesicles were stored at 370‡C;
under these conditions the rate of copper transport was not a¡ected
after at least 2 months of storage.
2.2. Immunoblotting analysis
Vesicles lysed in 0.2% SDS, and whole cell extract prepared as
described in [22], were size-fractionated on a 4^20% SDS-polyacryla-
mide gradient gel (Novex, San Diego, CA, USA). The gel was trans-
ferred overnight by electroblotting to nitrocellulose membrane. Pri-
mary antibodies used in this study were raised in rabbits.
Immunodetection of the Menkes protein was carried out using the
polyclonal antibody raised to the amino-terminus of MNK [22], and
the detection of Na/K-ATPase was carried out using polyclonal anti-
sera against Na/K-ATPase provided by Dr Judy Callaghan, Depart-
ment of Pathology and Immunology, Monash University, Victoria,
Australia [25]. The proteins were visualised with an enhanced chemi-
luminescence kit according to the manufacturer’s instructions (Boeh-
ringer, Mannheim, Germany).
2.3. Copper transport measurements
The copper transport assay was conducted in 40 mM histidine
bu¡er (pH 6.8) containing 100 mM KCl and 5 mM MgCl2 [26],
and supplemented with 25 WM DTT in the presence of 50 Wg/ml
vesicle protein and with or without 5 mM ATP at 37‡C. Copper
was added as a mixture of CuCl2 and 64CuCl2, speci¢c activity 260^
5800 mCi/mg (Australian Radioisotopes, Lucas Heights, NSW, Aus-
tralia). The transport assay was started by adding appropriate
amounts of vesicles to the reaction mixture. The rates of Cu uptake
were estimated by ¢ltering aliquots of the reaction mixture (at various
time points) through 0.45 Wm nitrocellulose ¢lters (Sartorius AG,
Goºttingen, Germany). The ¢lters were washed with 1.5 ml of reaction
bu¡er containing 1 mM CuCl2, and their radioactivity was measured
using an LKB-Wallac 1282 Compugamma Universal Gamma Coun-
ter (Finland). There was no signi¢cant di¡erence between the amount
of protein loaded onto the ¢lters and recovered from them (unpub-
lished data). The ¢lters were pre-blocked with 1 mM CuCl2 for at
least 1 h prior to experiments to minimise non-speci¢c Cu binding.
ATP-dependent copper transport was estimated by subtracting the
rate of Cu uptake in the absence of ATP from total rate measured in
the presence of ATP during the linear phase of the reaction (2^12
min). There were similar amounts of copper taken up by the vesicles
in the presence and absence of ATP within ¢rst 2 min of the reaction.
Within the same time frame there was no substantial di¡erence be-
tween the rates of Cu uptake into the CHO-K1 and CUR3 vesicles.
Therefore we considered that this rapid initial phase of the reaction
was due to a non-speci¢c Cu binding. Rates of Cu uptake were related
to total protein of vesicle fraction used (in the absence of pure MNK
as a standard it is not possible to quote rates related to actual MNK
protein concentration).
3. Results
In this study we used plasma membrane enriched vesicles
prepared from parental CHO-K1 cells and their copper resist-
ant variants, CUR2 and CUR3 [22] in order to investigate
and characterise Cu-translocating activity of the MNK P-
type ATPase. Western blot analysis supported previous ¢nd-
ings from this laboratory that CUR3 cells contained signi¢-
cantly elevated levels of MNK (Fig. 1A) [22]. There was a
large enrichment of MNK (V180 kDa) relative to total pro-
tein in the vesicle fraction as compared to the whole cell lysate
(Fig. 1A). Similarly there was a strong enrichment of vesicles
with Na/K-ATPase (V100 kDa) (Fig. 1B), a marker protein
for the plasma membrane.
Fig. 2 shows that while the rate of Cu uptake into CUR3
vesicles was markedly stimulated by ATP (Fig. 2A), its e¡ect
on the copper transport into CHO-K1 vesicles was insignif-
icant (Fig. 2B). Consequently, the rate of Cu uptake in CHO-
K1 vesicles was essentially undetectable using the current con-
ditions, while vesicles from CUR2 cells had 30% of CUR3
activity (Fig. 3, inset). This is consistent with the amounts
of MNK in CHO-K1, CUR2 and CUR3 vesicles (Fig. 1A).
Both ADP and a non-hydrolysable ATP homologue, AMP-
PCP (adenosine-5P-[L,Q-methylene]triphosphate), failed to sup-
port copper uptake (Fig. 3), suggesting the hydrolysis of ATP
is required for the copper transport activity. Having estab-
lished that Cu uptake correlates with the presence and quan-
tity of MNK, all other studies on catalytic properties of
chMNK were conducted using CUR3 vesicles.
It should be noted that ATP-dependent copper transport
into membrane vesicles can occur only when the ATP binding
site is oriented towards the cytosolic side (or bu¡er system in
vitro) which is the predicted topology of MNK in the cell [14^
17]. Reproducible Cu-transporting activities observed suggest
reproducible sideness of vesicles produced by the method as
shown previously [23]. While the ATP-independent copper
transport was insensitive to changing osmotic conditions
(data not shown), the level of ATP-driven copper uptake in
CUR3 vesicles in bu¡er supplemented with 1 M sucrose was
63 þ 8% (S.D.) of control (no added sucrose) levels. Also there
was no ATP-dependent transport observed when vesicles were
lysed with 0.1% Triton X-100 (data not shown), and copper
uptake was temperature dependent with the rate being re-
duced by 50% at 22‡C compared to the rate at 37‡C. Taken
together, these results provide strong evidence that in the
presence of ATP the copper was actively translocated into
the vesicles rather than bound to their surface.
DTT was an essential component of the reaction mixture,
as it presumably reduced Cu(II) to Cu(I). Thus in the presence
of trace amounts (6 1 WM) of DTT (from vesicle storage
bu¡er) the rate of ATP-dependent copper uptake was
17 þ 5% (S.D.) of control level. Because of the low stability
of MNK we were unable to obtain DTT-free samples of
vesicles, but it is likely that in the absence of DTT there would
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Fig. 1. Immunodetection of the V180 kDa MNK protein (A) and
V100 kDa Na/K-ATPase (B) on Western blots (see Section 2).
A: Lane 1: vesicles from CHO-K1 cells, 10 Wg protein; lanes 2 and
3: vesicles from CUR2 cells, 1 and 10 Wg protein; lanes 4 and 5:
vesicles from CUR3 cells, 0.1 and 1 Wg protein; lane 6: CHO-K1
whole cell homogenate, 100 Wg protein; lane 7: CUR2 whole cell
homogenate, 50 Wg protein; lane 8: CUR3 whole cell homogenate,
25 Wg protein. A non-speci¢c 100 kDa band was detected in whole
cell homogenates by the polyclonal antiserum used. B: Lane 1:
vesicles from CHO-K1 cells; lane 2: vesicles from CUR3 cells; lane
3: CHO-K1 whole cell homogenate; lane 4: CUR3 whole cell ho-
mogenate. Each lane was loaded with 10 Wg protein.
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be no active transport observed. These data are consistent
with electron spin resonance analysis, which showed a com-
plete disappearance of the Cu(II) pro¢le, when DTT was
added at equimolar concentrations to CuCl2 (data not
shown). Overall the data suggest that Cu(I) rather than
Cu(II) is actively transported by chMNK.
The chMNK protein of CUR3 vesicles displayed Michaelis-
Menten kinetics with respect to copper in the presence of ATP
and DTT. The apparent Km (7 þ 3 WM (S.D.)) and the appa-
rent Vmax (0.67 þ 0.38 nmol/mg/min (S.D.)) were estimated
from a Hanes-Woolf reciprocal plot (Fig. 4).
The uptake of copper into vesicles was signi¢cantly inhib-
ited by low concentrations of orthovanadate, which is a spe-
ci¢c inhibitor for P-type ATPases. The IC50 value was esti-
mated as 25 WM (Fig. 5). Structurally diverse alkylators of
protein sulphydryl groups N-ethylmaleimide (NEM) and p-
chloromercuribenzoate (PCMB) were potent inhibitors of
MNK activity (Fig. 5). Thus 5 WM NEM and 25 WM
PCMB reduced the rate of Cu uptake by at least 50% (Fig.
5). These results were obtained from experiments where NEM
and PCMB were preincubated with vesicles in a bu¡er con-
taining approximately 5^8 WM DTT for 5 min, and then di-
luted with 8 volumes of the reaction bu¡er to study Cu up-
take. Therefore the ¢nal concentrations of the inhibitors were
not su⁄cient to deplete DTT in the reaction bu¡er. The in-
hibition was irreversible, as the addition of 0.6 WM NEM and
3 WM PCMB (1/8 of estimated IC50) directly to the reaction
mixture failed to inhibit copper transport (results are not
shown). Ouabain (200 WM) an inhibitor of Na/K-ATPase,
had no e¡ect on copper uptake into CUR3 vesicles (100 þ 15%
(S.D.), compared to a no treatment control), indicating that
Cu transport was independent of Na/K-ATPase.
4. Discussion
In this study we provide the ¢rst biochemical evidence that
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Fig. 3. Copper uptake by the vesicles from CUR3 cells in the pres-
ence or absence of 5 mM ATP, or 5 mM ADP and 5 mM AMP-
PCP. *Signi¢cantly di¡erent from ‘ATP’ (P6 0.05) Inset: compara-
tive rates of ATP-dependent copper uptake by the vesicles from
CHO-K1, CUR2 and CUR3 cells. *Signi¢cantly di¡erent from
CUR3 (P6 0.05); 2signi¢cantly di¡erent from CUR2 (P6 0.05).
The results are presented as mean þ S.D.
Fig. 4. Michaelis-Menten plot of copper uptake by the vesicles from
CUR3 cells. Inset is Hanes-Woolf reciprocal plot. For technical rea-
sons, we were unable to measure the reaction rate at the concentra-
tions of copper higher than 15 WM. The values for apparent Km
and Vmax are presented as mean þ S.D., and the ¢gures are based
on the data from a representative experiment.
Fig. 2. Time-dependent copper uptake by the vesicles derived from
MNK overexpressing CUR3 cells (n = 4) (A), and their parental
CHO-K1 cells (n = 3) (B). The reaction was conducted in the pres-
ence of 2 WM CuCl2 containing 64CuCl2, 5 mM ATP, 25 WM DTT
and 50 Wg/ml vesicles. The data are presented as mean þ S.E.M. (us-
ing independent vesicle preparations).
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the MNK P-type ATPase functions as an ATP-dependent Cu-
translocating pump in mammalian cells. The rates of copper
transport correlated well with the levels of chMNK in the
vesicles prepared from CHO cells with di¡ering levels of the
MNK protein ([22]; Figs. 1A and 3). In addition, the data
showing the enzyme activity was stimulated by ATP, but not
by ADP or AMP-PCP and inhibited by low concentrations of
orthovanadate, a diagnostic inhibitor of P-type ATPases [27],
supported predictions based on DNA sequence that the en-
zyme is a P-type ATPase [14,15,17]. Copper-transporting ac-
tivity of vesicles derived from CHO cells carrying a stable
construct of hMNK has been demonstrated recently in our
laboratory and the apparent values for Km and Vmax were
similar to those presented here (Petris et al., manuscript in
preparation). Earlier studies from our laboratory indicated
the rate of copper e¥ux from whole CUR3 cells was 0.2^
0.3 nmol/mg/min ([22] ; unpublished observations) that is
only 2^3 times lower than the apparent value for Vmax found
here (0.67 nmol/mg/min). Solioz and Camakaris [28] recently
reported that the MNK protein from CUR3 cells catalyses the
formation of an acylphosphate intermediate when incubated
with ATP in vitro, which provided additional support that
MNK functions as a P-type ATPase.
Dijkstra et al. [29] and Bingham et al. [30] observed an
ATP-stimulated Cu uptake in membrane vesicles from rat
hepatocytes. The apparent Km values reported by these au-
thors are similar to those presented in this paper, 8.6 WM Cu
[29] and 2.5 WM Cu [30] versus 7 WM Cu. It has been reported
that MNK is not expressed in the liver of mammals [31], and,
although the liver enzyme has not been identi¢ed by Dijkstra
and Bingham [29,30], it is likely the activity was related to
that of the Wilson protein, a Cu-transporting ATPase found
in the liver, which has 54% homology with hMNK [32,33].
Our data strongly supports the notion that we were measuring
the MNK P-type ATPase, as Cu-transporting activity was
proportional to MNK concentration. Recently Payne and Gi-
tlin [34] have shown the hMNK protein functions in yeast to
complement CCC2 deletion mutants, and allows incorpora-
tion of Cu into the yeast protein Fet3p in yeast Golgi.
Although the yeast assay system supports the role of MNK
as a copper pump it does not permit detailed kinetic analy-
sis.
It is not clear whether it is ionic copper or a copper com-
plex which is presented to the MNK protein and transported
across the ion channel. It has been suggested that the cytosolic
copper chaperone, Atx1, may deliver copper to CCC2 [35]. A
homologue of Atx1, HAH1, has been identi¢ed in mammalian
cells and may function to transport Cu to the Menkes and/or
Wilson Cu-translocating ATPases [36]. It is possible that in
the in vitro system described in the present studies, DTT
functions as a surrogate copper donor for MNK. The process
may also require binding of Cu to the Cys-X-X-Cys ‘metal
binding motif(s)’ in the N-terminal domain of MNK. Site-
directed mutagenesis studies are in progress, and will provide
more details on the mechanism of Cu binding by MNK and in
particular which domains, motifs and residues are important
in Cu translocation.
Two structurally diverse alkylating agents, NEM and
PCMB, appeared to be potent irreversible inhibitors of Cu
uptake activity, indicating, not entirely surprisingly, the in-
volvement of the protein thiols in the transport of copper.
Qian et al. [7] demonstrated PCMB a¡ected the accumulation
and e¥ux of copper in human ¢broblasts in a manner sug-
gesting the inhibition of MNK Cu-transporting activity. It is
possible that cysteine thiols of the six -GMXCXXC- ‘metal
binding’ motif(s) found in the N-terminal domain of MNK
and/or the -CPC- motif in the ion transduction channel are
particularly important for the energy-dependent Cu transport.
These motif(s) may also be susceptible to reactive oxygen
species, whose formation is induced under various patholog-
ical conditions, e.g. in£ammation and carcinogenesis [37].
Thus it can be speculated that the accumulation of copper,
which is redox active in its own right, in in£amed tissues may
be caused by the inhibitory e¡ects of reactive oxygen species
on the catalytic activity of MNK [38]. The link between cop-
per accumulation, hepatic in£ammation and hepatocarcino-
genesis has been supported using Long-Evans Cinnamon
rats, an animal model of Wilson’s disease [39].
An important question of Cu metabolism that is yet to be
clari¢ed is the redox status of copper transported by the Cu P-
type ATPases. Under non-pathological conditions, high intra-
cellular concentrations of antioxidants would probably ensure
the reduction of Cu(II) to Cu(I). It has been postulated that
hMNK and its homologues in other species bind and trans-
port Cu(I) [40,41]. Moreover, Solioz and Odermatt [21] ob-
served ATP-dependent Cu transport catalysed by CopB (bac-
terial MNK homologue) under reducing conditions only. The
data presented in this paper supports the view that MNK
transports Cu(I) rather than Cu(II), but further studies are
required to establish this conclusively.
Recent work carried out in our laboratory demonstrated
that Cu can regulate MNK by causing alteration of its sub-
cellular location [42] ; MNK is relocalised via vesicular traf-
¢cking from the trans-Golgi network to the plasma membrane
in the presence of high extracellular concentrations of copper.
Copper-transporting activity of MNK explains, at least parti-
ally, the physiological signi¢cance of this phenomenon. MNK
in the trans-Golgi network is predicted to donate Cu to Cu-
dependent enzymes in the secretory pathway, e.g. lysyl amine
oxidase. It is hypothesised that excess Cu is sensed by MNK
in the trans-Golgi network, and then may stimulate budding
and tra⁄cking of vesicles to the plasma membrane. It is pos-
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Fig. 5. Inhibition of copper uptake by sodium orthovanadate, N-
ethylmaleimide and p-chloromercuribenzoic acid. *P6 0.05 com-
pared to a ‘0 inhibitor’ control (Student’s t-test). The results pre-
sented are mean þ S.D. ‘Residual activity’ is the percentage of ‘0 in-
hibitor’ control (100%).
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sible that MNK pumps copper into these vesicles and releases
it from the cell once the vesicles fuse with the plasma mem-
brane. Alternatively, the vesicles fuse with the plasma mem-
brane and then start pumping copper actively from the cell. In
any case, the combination of MNK vesicular tra⁄cking with
its Cu-transporting activity forms an e⁄cient detoxi¢cation
and Cu homeostatic mechanism [22]. In addition, MNK cop-
per-translocating activity across the basolateral membrane of
polar gut epithelial cells may provide the mechanism for Cu
absorption, as Menkes patients accumulate Cu in these cells
[3].
In conclusion, the information presented here provides an
insight into the critical role of the ubiquitous MNK in copper
homeostasis in mammalian cells and provides the ¢rst direct
biochemical evidence that it functions as a copper-transport-
ing P-type ATPase. The study opens the opportunity to gain
more information on the role of various domains and motifs
of the enzyme in its catalytic function through use of engi-
neered mutant MNK constructs expressed in cultured cells. In
addition these ¢ndings have important therapeutic implica-
tions. Kaler et al. [43,44] have suggested that favourable out-
comes can be obtained by copper therapy of Menkes disease
patients who express MNK, which has residual function,
whilst copper therapy may be of no value in patients who
do not express a functional MNK transporter. Assays of cop-
per-transporting activity using vesicles from cells overexpres-
sing MNK constructs containing patient’s mutations should
allow assessment of candidate patients for copper therapy.
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